Arbutus Biopharma Corporation Stock Price, News & Analysis (NASDAQ:ABUS)

$5.75 -0.10 (-1.71 %)
(As of 11/18/2017 07:32 AM ET)
Previous Close$5.75
Today's Range$5.90 - $5.70
52-Week Range$2.35 - $8.25
Volume146,452 shs
Average Volume250,955 shs
Market Capitalization$316.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06

About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:ABUS
  • CUSIP: N/A
  • Web: www.arbutusbio.com
Debt:
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 11.03%
  • Quick Ratio: 11.03%
Sales & Book Value:
  • Annual Sales: $1.5 million
  • Price / Sales: 211.03
  • Cash Flow: $5.93 per share
  • Price / Cash: 0.97
  • Book Value: $3.04 per share
  • Price / Book: 1.89
Profitability:
  • Trailing EPS: ($4.97)
  • Net Income: ($384,160,000.00)
  • Return on Equity: -34.98%
  • Return on Assets: -24.76%
Misc:
  • Employees: 122
  • Outstanding Shares: 55,050,000
 

Frequently Asked Questions for Arbutus Biopharma Corporation (NASDAQ:ABUS)

What is Arbutus Biopharma Corporation's stock symbol?

Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma Corporation's earnings last quarter?

Arbutus Biopharma Corporation (NASDAQ:ABUS) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.11. The biopharmaceutical company had revenue of $4.10 million for the quarter, compared to analyst estimates of $3.37 million. View Arbutus Biopharma Corporation's Earnings History.

When will Arbutus Biopharma Corporation make its next earnings announcement?

Arbutus Biopharma Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, March, 20th 2018. View Earnings Estimates for Arbutus Biopharma Corporation.

Where is Arbutus Biopharma Corporation's stock going? Where will Arbutus Biopharma Corporation's stock price be in 2017?

6 equities research analysts have issued 12 month price targets for Arbutus Biopharma Corporation's stock. Their forecasts range from $5.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's share price to reach $13.00 in the next year. View Analyst Ratings for Arbutus Biopharma Corporation.

What are Wall Street analysts saying about Arbutus Biopharma Corporation stock?

Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:

  • 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (11/7/2017)
  • 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)

Who are some of Arbutus Biopharma Corporation's key competitors?

Who are Arbutus Biopharma Corporation's key executives?

Arbutus Biopharma Corporation's management team includes the folowing people:

  • Vivek Ramaswamy, Chairman of the Board (Age 30)
  • Mark J. Murray Ph.D., President, Chief Executive Officer, Director (Age 67)
  • Bruce G. Cousins, Chief Financial Officer, Executive Vice President (Age 55)
  • Elizabeth Howard, Executive Vice President, General Counsel (Age 62)
  • Peter Lutwyche Ph.D., Chief Technology Officer (Age 50)
  • Michael Joseph Sofia, Chief Scientific Officer (Age 57)
  • William Thomas Symonds III, Chief Development Officer, Director (Age 48)
  • Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets (Age 59)
  • Patrick T. Higgins, Chief Business Officer (Age 58)
  • Daniel D. Burgess, Director (Age 55)

Who owns Arbutus Biopharma Corporation stock?

Arbutus Biopharma Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.57%), Ladenburg Thalmann Financial Services Inc. (3.21%), K2 Principal Fund L.P. (0.45%), Point72 Asset Management L.P. (0.41%) and OxFORD Asset Management LLP (0.23%). View Institutional Ownership Trends for Arbutus Biopharma Corporation.

Who sold Arbutus Biopharma Corporation stock? Who is selling Arbutus Biopharma Corporation stock?

Arbutus Biopharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc. and K2 Principal Fund L.P.. View Insider Buying and Selling for Arbutus Biopharma Corporation.

Who bought Arbutus Biopharma Corporation stock? Who is buying Arbutus Biopharma Corporation stock?

Arbutus Biopharma Corporation's stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., RTW Investments LP and OxFORD Asset Management LLP. View Insider Buying and Selling for Arbutus Biopharma Corporation.

How do I buy Arbutus Biopharma Corporation stock?

Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma Corporation's stock price today?

One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $5.75.

How big of a company is Arbutus Biopharma Corporation?

Arbutus Biopharma Corporation has a market capitalization of $316.55 million and generates $1.5 million in revenue each year. The biopharmaceutical company earns ($384,160,000.00) in net income (profit) each year or ($4.97) on an earnings per share basis. Arbutus Biopharma Corporation employs 122 workers across the globe.

How can I contact Arbutus Biopharma Corporation?

Arbutus Biopharma Corporation's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma Corporation (NASDAQ ABUS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Arbutus Biopharma Corporation (NASDAQ:ABUS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $13.00 (126.09% upside)

Consensus Price Target History for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Price Target History for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Analysts' Ratings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Leerink SwannReiterated RatingMarket Perform$4.00 -> $5.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $13.00HighView Rating Details
9/20/2017WedbushReiterated RatingOutperform$9.00MediumView Rating Details
9/13/2017Chardan CapitalReiterated RatingBuyHighView Rating Details
6/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$32.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
12/21/2015Royal Bank Of CanadaLower Price Target$20.00 -> $12.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Earnings by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Earnings History by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/20/2018        
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corporation (NASDAQ:ABUS)
2017 EPS Consensus Estimate: ($1.53)
2018 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.25)($0.30)
Q2 20173($0.42)($0.39)($0.40)
Q3 20173($0.43)($0.39)($0.41)
Q4 20173($0.44)($0.39)($0.41)
Q1 20182($0.38)($0.36)($0.37)
Q2 20182($0.39)($0.36)($0.38)
Q3 20182($0.40)($0.37)($0.39)
Q4 20182($0.41)($0.38)($0.40)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arbutus Biopharma Corporation (NASDAQ ABUS)

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 66.93%
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Michael J SofiaInsiderSell10,000$8.00$80,000.00View SEC Filing  
8/15/2017Michael J SofiaInsiderSell30,000$3.70$111,000.00View SEC Filing  
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arbutus Biopharma Corporation (NASDAQ ABUS)

Source:
DateHeadline
Arbutus LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to US Food and Drug ... - GlobeNewswire (press release)Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to US Food and Drug ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 8:25 AM
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for PatisiranArbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
finance.yahoo.com - November 16 at 3:35 PM
Arbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from EMAArbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from EMA
www.streetinsider.com - November 14 at 3:24 AM
Arbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from ... - StreetInsider.comArbutus Biopharma (ABUS) Says LNP Licensee Alnylam (ANLY) Receives Accelerated Assessment of Patisiran from ... - StreetInsider.com
www.streetinsider.com - November 13 at 10:23 PM
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
finance.yahoo.com - November 13 at 10:23 PM
Equities Analysts Issue Forecasts for Arbutus Biopharma Corporations FY2017 Earnings (ABUS)Equities Analysts Issue Forecasts for Arbutus Biopharma Corporation's FY2017 Earnings (ABUS)
www.americanbankingnews.com - November 9 at 8:45 AM
Arbutus Biopharma Corporation (ABUS) Upgraded by Zacks Investment Research to HoldArbutus Biopharma Corporation (ABUS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - November 7 at 11:50 PM
Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 4:49 PM
Arbutus Biopharma Corporation (ABUS) Earns "Market Perform" Rating from Leerink SwannArbutus Biopharma Corporation (ABUS) Earns "Market Perform" Rating from Leerink Swann
www.americanbankingnews.com - November 7 at 11:32 AM
Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 6, 2017Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 6, 2017
finance.yahoo.com - November 6 at 4:06 PM
Arbutus Biopharma Corporation (ABUS) Given Average Rating of "Buy" by BrokeragesArbutus Biopharma Corporation (ABUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 3:42 PM
Arbutus Biopharma Corporation (ABUS) Expected to Post Quarterly Sales of $790,000.00Arbutus Biopharma Corporation (ABUS) Expected to Post Quarterly Sales of $790,000.00
www.americanbankingnews.com - November 6 at 6:04 AM
Arbutus Biopharmas (ABUS) CEO Mark Murray on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaArbutus Biopharma's (ABUS) CEO Mark Murray on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 5 at 3:26 PM
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 3:14 PM
Edited Transcript of ABUS earnings conference call or presentation 2-Nov-17 8:15pm GMTEdited Transcript of ABUS earnings conference call or presentation 2-Nov-17 8:15pm GMT
finance.yahoo.com - November 3 at 10:22 AM
Arbutus Announces Corporate Update and Third Quarter 2017 Financial ResultsArbutus Announces Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 8:28 PM
Arbutus Biopharma Corporation to Host Earnings CallArbutus Biopharma Corporation to Host Earnings Call
finance.yahoo.com - November 2 at 3:25 PM
Should You Buy Arbutus Biopharma Corporation (ABUS)?Should You Buy Arbutus Biopharma Corporation (ABUS)?
finance.yahoo.com - November 1 at 3:24 PM
Arbutus Biopharma Corp. – Value Analysis (NASDAQ:ABUS) : October 27, 2017Arbutus Biopharma Corp. – Value Analysis (NASDAQ:ABUS) : October 27, 2017
finance.yahoo.com - October 27 at 5:31 PM
Arbutus Biopharma Corp. breached its 50 day moving average in a Bearish Manner : ABUS-US : October 26, 2017Arbutus Biopharma Corp. breached its 50 day moving average in a Bearish Manner : ABUS-US : October 26, 2017
finance.yahoo.com - October 26 at 11:37 AM
Aptose Biosciences (APTO) versus Arbutus Biopharma Corporation (ABUS) Financial ReviewAptose Biosciences (APTO) versus Arbutus Biopharma Corporation (ABUS) Financial Review
www.americanbankingnews.com - October 25 at 8:37 AM
Arbutus Biopharma Corporation (ABUS) Scheduled to Post Earnings on WednesdayArbutus Biopharma Corporation (ABUS) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:30 AM
Arbutus Presents HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)Arbutus Presents HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)
globenewswire.com - October 24 at 8:24 PM
Arbutus Presents HBV Data at 2017 AASLD Liver MeetingArbutus Presents HBV Data at 2017 AASLD Liver Meeting
feeds.benzinga.com - October 24 at 8:25 AM
Arbutus out-licenses LNP technology to Gritstone Oncology - Seeking AlphaArbutus out-licenses LNP technology to Gritstone Oncology - Seeking Alpha
seekingalpha.com - October 18 at 3:42 PM
Arbutus Biopharma (ABUS) and Gritstone Oncology Reports LNP ... - StreetInsider.comArbutus Biopharma (ABUS) and Gritstone Oncology Reports LNP ... - StreetInsider.com
www.streetinsider.com - October 18 at 3:42 PM
Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer PatientsGritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
finance.yahoo.com - October 18 at 3:42 PM
Bucks biopharm firm signs licensing deal with California onco-immunology companyBucks biopharm firm signs licensing deal with California onco-immunology company
finance.yahoo.com - October 18 at 3:42 PM
Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences - GlobeNewswire (press release)Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences - GlobeNewswire (press release)
globenewswire.com - October 16 at 3:32 PM
Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant SciencesArbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 16 at 3:32 PM
Contrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)Contrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)
www.americanbankingnews.com - October 16 at 10:58 AM
Arbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.38 Per ShareArbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - October 15 at 2:24 PM
Arbutus Biopharma Corporation (ABUS) Receives Consensus Rating of "Buy" from BrokeragesArbutus Biopharma Corporation (ABUS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 4:46 PM
Insider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 10,000 Shares of StockInsider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - October 5 at 7:44 PM
Arbutus Biopharma Corp. (ABUS) Has Broken Out To A New High For The YearArbutus Biopharma Corp. (ABUS) Has Broken Out To A New High For The Year
www.rttnews.com - October 4 at 3:10 PM
JMP Securities Reaffirms "Outperform" Rating for Arbutus Biopharma Corporation (ABUS)JMP Securities Reaffirms "Outperform" Rating for Arbutus Biopharma Corporation (ABUS)
www.americanbankingnews.com - October 4 at 1:42 PM
Arbutus Biopharma Corporation to Post Q1 2018 Earnings of ($0.38) Per Share, Wedbush Forecasts (ABUS)Arbutus Biopharma Corporation to Post Q1 2018 Earnings of ($0.38) Per Share, Wedbush Forecasts (ABUS)
www.americanbankingnews.com - October 4 at 11:04 AM
Arbutus Biopharma: Updates To Thesis Part 2 - Seeking AlphaArbutus Biopharma: Updates To Thesis Part 2 - Seeking Alpha
seekingalpha.com - October 4 at 8:12 AM
Arbutus to Present HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)Arbutus to Present HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)
globenewswire.com - October 3 at 3:06 PM
Arbutus to Present HBV Data at 2017 AASLD Liver MeetingArbutus to Present HBV Data at 2017 AASLD Liver Meeting
finance.yahoo.com - October 3 at 3:06 PM
$116M deal for Bucks County company working on hepatitis B cure$116M deal for Bucks County company working on hepatitis B cure
www.bizjournals.com - October 2 at 3:11 PM
Arbutus Biopharma (ABUS) Receives $116M Strategic Investment from Roivant SciencesArbutus Biopharma (ABUS) Receives $116M Strategic Investment from Roivant Sciences
www.streetinsider.com - October 2 at 3:10 PM
Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4
finance.yahoo.com - October 2 at 3:10 PM
Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceArbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - October 2 at 3:10 PM
Arbutus to Receive $116 Million Strategic Investment from Roivant SciencesArbutus to Receive $116 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 2 at 3:10 PM
Roivant Makes $116 Million Investment In Arbutus, Backing Battle With ModernaRoivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna
finance.yahoo.com - October 2 at 3:10 PM
Head to Head Comparison: Arbutus Biopharma Corporation (ABUS) and Its PeersHead to Head Comparison: Arbutus Biopharma Corporation (ABUS) and Its Peers
www.americanbankingnews.com - October 2 at 12:22 PM
 Analysts Expect Arbutus Biopharma Corporation (ABUS) to Announce -$0.38 EPS Analysts Expect Arbutus Biopharma Corporation (ABUS) to Announce -$0.38 EPS
www.americanbankingnews.com - September 26 at 10:10 PM
Arbutus Presents HBV Data at Upcoming Scientific ConferencesArbutus Presents HBV Data at Upcoming Scientific Conferences
feeds.benzinga.com - September 22 at 5:49 PM
William Blair Weighs in on Arbutus Biopharma Corporations Q1 2018 Earnings (ABUS)William Blair Weighs in on Arbutus Biopharma Corporation's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - September 22 at 9:00 AM

Social Media

Financials

Chart

Arbutus Biopharma Corporation (NASDAQ ABUS) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.